乳腺癌内分泌治疗的新思路和临床实践课件.ppt

乳腺癌内分泌治疗的新思路和临床实践BaselineUltrasound12345678910100102030405060nEndometrialthickness(mm)乳腺癌内分泌治疗的新思路和临床实践Medianendometrialthickness024681001224Endometrialthickness(mm)‘Arimidex’TamoxifenCombinationTime(months)乳腺癌内分泌治疗的新思路和临床实践AvsTCvsTAvsC0.230.460.500.020.110.51ORpvalueATCA,‘Arimidex’;C,combination;T,tamoxifen3136%patientsPredefinedadverseevents

Endometrialcancer乳腺癌内分泌治疗的新思路和临床实践ATACSummaryAnastrozoleissuperiortotamoxifen

intermsof:Disease-freesurvivalin:

Overallpopulation(HR=0.83)

Receptor-positivepatients(HR=0.78)

Incidenceofcontralateralbreast

cancerin:

Overallpopulation(OR=0.42)乳腺癌内分泌治疗的新思路和临床实践ConclusionsAnastrozoleisthefirstandonlyAItoshowsuperiorefficacyandimprovedtolerabilitycomparedwithtamoxifeninthetreatmentofEBCOverallrisk-benefitassessmentsupportsanastrozolebecomingthefutureadjuvanttreatmentofchoiceinpostmenopausalwomenAnastrozolealsoshowspromiseforthechemopreventionofbreastcancer乳腺癌内分泌治疗的新思路和临床实践AnalysisoftheIncidenceofNew(Contralateral)BreastPrimariesTimetofirstcontralateralnewprimary(months)0612182430364209899100ProportionwithoutCLBCa(%)AnastrozoleTamoxifenCombinationOR 95%CI p-valueANvsTAM 0.42 0.22–0.79 0.0068CombvsTAM 0.84 0.51–1.40 0.5132乳腺癌内分泌治疗的新思路和临床实践Arimidex(Anastrozole)

inBreastcancerprevention:

DesignofIBISII

anddatafromATAC乳腺癌内分泌治疗的新思路和临床实践Whyusean

AromataseInhibitor?AtleastaseffectiveastamoxifeninABCATACtrialprovidesearlywarningon

sideeffectsATACtrialprovidesefficacydatainearlybreastcanceratallendpoints;strikingreductionincontralateralbreastcancereventsVerylowside-effectprofile乳腺癌内分泌治疗的新思路和临床实践ATAC:incidenceofnew(contralateral)breastprimariesinITTpopulation9

invasive05101520253035Tamoxifen(n=3116)‘Arimidex’(n=3125)Combination(n=3125)5D